- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02595879
Triapin mit Chemotherapie und Strahlentherapie bei der Behandlung von Patienten mit IB2-IVA-Zervix- oder Vaginalkrebs
Phase-I-Dosis-Eskalations-Bioverfügbarkeitsstudie von oralem Triapin in Kombination mit gleichzeitiger Radiochemotherapie bei lokal fortgeschrittenem Gebärmutterhalskrebs (LACC) und Vaginalkrebs
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.
Studienübersicht
Status
Bedingungen
- Fortgeschrittenes vaginales Adenokarzinom
- Fortgeschrittenes vaginales adenosquamöses Karzinom
- Fortgeschrittenes vaginales Plattenepithelkarzinom
- Stadium IB2 Gebärmutterhalskrebs AJCC v6 und v7
- Stadium II Gebärmutterhalskrebs AJCC v7
- Vaginalkrebs im Stadium II AJCC v6 und v7
- Vaginalkrebs im Stadium III AJCC v6 und v7
- Gebärmutterhalskrebs im Stadium IIIB AJCC v6 und v7
- Stadium IVA Gebärmutterhalskrebs AJCC v6 und v7
- Vaginalkrebs im Stadium IVA AJCC v6 und v7
- Fortgeschrittenes zervikales Adenokarzinom
- Fortgeschrittenes zervikales adenosquamöses Karzinom
- Fortgeschrittenes zervikales Plattenepithelkarzinom
Intervention / Behandlung
- Arzneimittel: Cisplatin
- Verfahren: Magnetic Resonance Imaging
- Sonstiges: Pharmacological Study
- Verfahren: Biospecimen Collection
- Strahlung: Intensity-Modulated Radiation Therapy
- Verfahren: Computed Tomography
- Verfahren: Positron Emission Tomography
- Strahlung: Brachytherapy
- Strahlung: External Beam Radiation Therapy
- Sonstiges: Fludeoxyglucose F-18
- Strahlung: High-Dose Rate Brachytherapy
- Arzneimittel: Triapine
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy.
II. To determine the oral bioavailability of triapine. III. To describe the pharmacokinetics (PK) of oral and intravenous triapine.
SECONDARY OBJECTIVES:
I. To determine whether the metabolic complete response (mCR) rate of oral triapine in combination with cisplatin chemoradiation using fludeoxyglucose F 18 (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) at post-therapy (3-month) is at least 70%.
II. To determine clinical overall response rate, progression-free survival, and overall survival.
III. To determine the correlation of methemoglobin proportion (%) and triapine pharmacokinetic exposure.
EXPLORATORY OBJECTIVE:
I. To determine whether active human immunodeficiency virus (HIV) antiretroviral therapy impacts the antitumor activity of triapine.
OUTLINE: This is a dose-escalation study of triapine.
Patients undergo pelvic external beam radiation therapy (EBRT) or intensity modulated radiation therapy (IMRT) 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of low dose rate (LDR) brachytherapy in week 6 or 5 fractions of high dose rate (HDR) brachytherapy at week 4 or 5. Patients also receive triapine intravenously (IV) over 120 minutes on day 1 and orally (PO) on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo magnetic resonance imaging (MRI) and FDG-PET/CT during follow-up.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- University of Alabama at Birmingham Cancer Center
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Vereinigte Staaten, 90033
- Los Angeles General Medical Center
-
Pasadena, California, Vereinigte Staaten, 91105
- Keck Medical Center of USC Pasadena
-
-
Kansas
-
Fairway, Kansas, Vereinigte Staaten, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- University of Kansas Cancer Center
-
Overland Park, Kansas, Vereinigte Staaten, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood, Kansas, Vereinigte Staaten, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- University of Kentucky/Markey Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Rogel Cancer Center
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Vereinigte Staaten, 48334
- Weisberg Cancer Treatment Center
-
-
New Jersey
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rutgers Cancer Institute of New Jersey
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Hillman Cancer Center
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Vereinigte Staaten, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patient has a new, untreated histologic diagnosis of stage IB2 (> 5 cm), II, IIIB, IIIC or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina not amenable to curative surgical resection alone; the presence or absence of lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; the patient must be able to tolerate imaging requirements of an 18F-FDG PET/CT scan
-
Age >= 18 years old
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
-
Life expectancy greater than 6 months
-
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
-
Platelets >= 100 x 10^9/L
-
Hemoglobin (Hgb) >= 10.0 g/dL (blood transfusions to reach this amount are allowed)
-
Serum creatinine =< 1.5 mg/dL to receive weekly cisplatin
- If serum creatinine is between 1.5 and 1.9 mg/dL, patients are eligible for cisplatin if the estimated creatinine clearance (CCr) is > 30 ml/min (for the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used)
-
Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (in patients with known Gilbert syndrome, a total bilirubin =< 3.0 x ULN, with direct bilirubin =< 1.5 x ULN)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
-
Able to take oral medication
-
Not pregnant and not breastfeeding; the effects of triapine on the developing human fetus are unknown; for this reason as well as because heterocyclic carboxaldehydethiosemicarbazones and radiation are known to be teratogenic, women of child-bearing potential and men must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; patient must have documented negative urine pregnancy test must be resulted within 7 days before initiating protocol therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine, breastfeeding should be discontinued if the mother is treated with triapine; these potential risks may also apply to other agents used in this study
-
For HIV and hepatitis B/C (HEPB/C):
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for the dose escalation portion of this trial; for those patients who are enrolled in the HIV positive (+) expansion cohort, they must be HIV infected and be on retroviral therapy with an undetectable viral load within 6 months of enrollment
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured; for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Able to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Patient has had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix)
- Patients are excluded if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician
- Patients receiving any other investigational agents
- Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded due to an inability to administer the antidote for methemoglobinemia, methylene blue; pre-registration testing for G6PD is at the investigator's discretion and is not required for study enrollment
- Patients who are taking any medication associated with methemoglobinemia; medication must be discontinued and must have a washout period of 4 halflives or 4 weeks, whichever is shorter
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by medication, =< 200 mg/dL allowed)
- Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment are ineligible
- Patients scheduled to be treated with adjuvant consolidation chemotherapy at the conclusion of their standard chemoradiation
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Treatment (triapine, chemoradiation)
Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up. |
Given IV
Andere Namen:
Undergo MRI
Andere Namen:
Correlative studies Undergo collection of blood samples
Andere Namen:
Undergo IMRT
Andere Namen:
Undergo FDG-PET/CT
Andere Namen:
Undergo FDG-PET/CT
Andere Namen:
Undergo LDR brachytherapy
Andere Namen:
Undergo pelvic EBRT
Andere Namen:
Undergo FDG-PET/CT
Andere Namen:
Undergo HDR brachytherapy
Andere Namen:
Given IV and PO
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Eliminationshalbwertszeit (t 1/2)
Zeitfenster: Bis zu 24 Stunden nach der Dosierung
|
Bis zu 24 Stunden nach der Dosierung
|
|
|
Maximum Tolerated Dose (MTD)
Zeitfenster: Up to 5 weeks
|
The MTD was determined following a standard 3+3 design is as follows: Escalation at 0/3 DLTs, dose-reduction if >1/3 DLT, and expansion to 6 if 1/3 DLTs. DLT is defined as the severe toxicity event that leads to the termination of the treatment as defined in section 5.5. The highest dose level where <2/6 DLTs are observed will be declared MTD |
Up to 5 weeks
|
|
Number of Patients Who Experienced a DLT
Zeitfenster: Up to 5 weeks
|
Number of patients that experienced a DLT, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. DLTs are defined as the following adverse events if considered at least "possibly related" to a component of the study therapy and which occur from the start of treatment until completion of EBRT, prior to initiation of brachytherapy (i.e. the first 5 weeks if no treatments are missed): Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 3 toxicity not resolved with maximal intervention to Grade 0-2 over 7 days (except alopecia and fatigue); Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 4 toxicity; Any other non-hematologic toxicity ≥Grade 3; Any hematologic toxicity of ≥ Grade 4; Grade ≥3 dyspnea; Inability to deliver at least 20 of the scheduled 25 administrations of triapine at the planned dose, allowing for 2 weeks to make up missed radiation days. Inability to deliver |
Up to 5 weeks
|
|
Bioavailability of Triapine
Zeitfenster: Up to 2 weeks
|
The oral bioavailability of the oral form of the triapine will be measured as a numeric value using mass spectrophotometry. |
Up to 2 weeks
|
|
Cmax
Zeitfenster: Up to 24 hours after dosing
|
Maximum concentration |
Up to 24 hours after dosing
|
|
Tmax
Zeitfenster: Up to 24 hours after dosing
|
Time to maximum concentration, |
Up to 24 hours after dosing
|
|
AUC
Zeitfenster: Up to 24 hours after dosing
|
Area Under the Concentration-Time Curve (AUC 0-last) |
Up to 24 hours after dosing
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fludeoxyglucose F18-Positron Emission Tomography Computed Tomography Metabolic Complete Response (mCR) Rate
Zeitfenster: At 3 months post-treatment
|
The mCR rate at recommended phase 2 dose, defined as a metabolic complete response on PET/CT will be defined as greater than -66% reduction in tumor FDG uptake at sites of abnormal tumor FDG uptake noted on pre-treatment FDG-PET study (considering normal cardiac or liver blood pool). |
At 3 months post-treatment
|
|
Clinical Overall Response Rate
Zeitfenster: 3 months post-treatment
|
Clinical response at the recommended phase 2 dose per RECIST v1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
3 months post-treatment
|
|
Progression Free Survival (PFS)
Zeitfenster: Up to 4 years and 2 months from start of treatment
|
Median number of months that patients survive without disease progression from end of treatment. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 4 years and 2 months from start of treatment
|
|
Overall Survival (OS)
Zeitfenster: Up to 4 years and 2 months from start of treatment
|
Median number of months that patients remain alive after end of treatment. |
Up to 4 years and 2 months from start of treatment
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Sarah E Taylor, University of Pittsburgh Cancer Institute LAO
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Uteruserkrankungen
- Genitalerkrankungen, weiblich
- Genitale Neubildungen, weiblich
- Gebärmutterhalskrankheiten
- Uterusneoplasmen
- Gebärmutterhalstumoren
- Untersuchungstechniken
- Therapeutika
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Kohlenhydrate
- Physikalische Phänomene
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Elemente
- Metalle
- Organisationen
- Gesundheitsökonomie und Organisationen
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Metalle, schwer
- Platinverbindungen
- Strahlentherapie
- Desoxyglucose
- Desoxyzucker
- Übergangselemente
- Strahlentherapie, konform
- Strahlentherapie, computergestützt
- Fluordesoxyglucose F18
- Cisplatin
- 1,2-Diaminocyclohexanplatin-II-Citrat
- Strahlung
- Kongresse als Thema
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Platin
- Strahlentherapie, intensität moduliert
- Brachytherapie
- 3-Aminopyridin-2-carboxaldehyd Thiosemicarbazon
Andere Studien-ID-Nummern
- NCI-2015-01907
- NCI-2015-01907 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- HCC 15-157
- UPCI 15-157
- 15-157
- 9892 (Andere Kennung: CTEP)
- UM1CA186690 (US NIH Stipendium/Vertrag)
- 9892 (Andere Kennung: UPMC Hillman Cancer Center LAO)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .